Skip to main content
SpringerLink
Log in

Classification of Lymphomas

  • Chapter
  • First Online:
Concise Guide to Hematology

  • 2799 Accesses

Abstract

Lymphomas are hematologic malignancies arising from lymphocytes, and this group of diseases has seen drastic changes in both treatment and diagnosis over the last 50 years. What once could be described as simply Hodgkin or non-Hodgkin is now divided and subdivided into a wide array of diseases based on histology, immunohistochemistry, genetic testing evaluating specific chromosomal translocations, and other techniques. With the recent release of the 2016 update of the World Health Organization classification system for lymphomas, the latest advances and discoveries have been integrated into its organization of lymphoma into five broad categories: mature B cell neoplasms, mature T and NK cell neoplasms, Hodgkin lymphoma, posttransplant lymphoproliferative disorder, and histiocytic/dendritic cell neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Swerdlow SH, Campo E, Harris N, et al. WHO classification of tumors of the hematopoietic and lymphoid tissues. Lyon: IARC; 2017.

    Google Scholar 

  2. Brown TC, Peters MV, Bergsagel DE, Reid J. A retrospective analysis of the clinical results in relation to the Rappaport histological classification. Br J Cancer Suppl. 1975;2:174–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Robb-Smith AHT. U.S. National Cancer Institute working formulation of non-Hodgkin’s lymphomas for clinical use. Lancet. 1982;320(8295):432–4.

    Article  Google Scholar 

  4. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.

    Article  CAS  PubMed  Google Scholar 

  5. Swerdlow SH, Campo E, Harris N, et al. WHO classification of tumors of the hematopoietic and lymphoid tissues. Lyon: IARC; 2008.

    Google Scholar 

  6. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909–18.

    Google Scholar 

  7. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B cell lymphoma. Blood. 2000;95(7):2253–61.

    CAS  PubMed  Google Scholar 

  8. Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. 2017;3:16096.

    Article  PubMed  Google Scholar 

  9. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.

    Article  PubMed  Google Scholar 

  11. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Strati P, Shanafelt TD. Monoclonal B cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126(4):454–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Fung SS, Hillier KL, Leger CS, et al. Clinical progression and outcome of patients with monoclonal B cell lymphocytosis. Leuk Lymphoma. 2007;48(6):1087–91.

    Article  PubMed  Google Scholar 

  14. Bosga-bouwer AG, Van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood. 2003;101(3):1149–54.

    Article  CAS  PubMed  Google Scholar 

  15. Kato S, Lippman SM, Flaherty KT, Kurzrock R. The conundrum of genetic “Drivers” in benign conditions. J Natl Cancer Inst. 2016;108(8).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bacon CM, Du MQ, Dogan A. Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. J Clin Pathol. 2007;60(4):361–72.

    Article  CAS  PubMed  Google Scholar 

  18. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93(11):3601–9.

    Article  CAS  PubMed  Google Scholar 

  19. Kwee I, Rancoita PM, Rinaldi A, et al. Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica. 2011;96(7):1064–6.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Van den Brand M, Van Krieken JH. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica. 2013;98(7):1003–13.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116(9):1479–88.

    Article  CAS  PubMed  Google Scholar 

  22. Isaacson PG, Chott A, Nakamura S, Muller-Hermelink HK, Harris NL, Swerdlow SH. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 214–7.

    Google Scholar 

  23. Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenström’s macroglobulinemia. N Engl J Med. 2015;373(6):584–6.

    Article  CAS  PubMed  Google Scholar 

  24. Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom’s macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol. 2003;30(2):182–6.

    Article  PubMed  Google Scholar 

  25. Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology. 1987;37(9):1506–14.

    Article  CAS  PubMed  Google Scholar 

  26. Andritsos LA, Grever MR. Historical overview of hairy cell leukemia. Best Pract Res Clin Haematol. 2015;28(4):166–74.

    Article  PubMed  Google Scholar 

  27. Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma. 1994;13(3–4):307–16.

    Article  CAS  PubMed  Google Scholar 

  28. Grever MR, Abdel-wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Grever MR, Blachly JS, Andritsos LA. Hairy cell leukemia: update on molecular profiling and therapeutic advances. Blood Rev. 2014;28(5):197–203.

    Article  CAS  PubMed  Google Scholar 

  30. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980–2007. JAMA. 2011;305(14):1450–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B cell lymphoma. Cancer Epidemiol. 2015;39(6):1103–12.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–95.

    Article  CAS  PubMed  Google Scholar 

  34. Katzenberger T, Lohr A, Schwarz S, et al. Genetic analysis of de novo CD5+ diffuse large B cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood. 2003;101(2):699–702.

    Article  CAS  PubMed  Google Scholar 

  35. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(3):815–21.

    Article  CAS  PubMed  Google Scholar 

  36. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360–5.

    Article  CAS  PubMed  Google Scholar 

  37. Savage KJ, Johnson NA, Ben-neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–7.

    Article  CAS  PubMed  Google Scholar 

  38. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777–83.

    Article  CAS  PubMed  Google Scholar 

  39. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756–67.

    Article  CAS  PubMed  Google Scholar 

  41. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.

    Article  PubMed  Google Scholar 

  42. Jaffe ES, Nicolae A, Pittaluga S. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol. 2013;26(Suppl 1):S71–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402–8.

    Article  CAS  PubMed  Google Scholar 

  45. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2012;83(2):293–302.

    Article  PubMed  Google Scholar 

  46. Castellar ERP, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–80.

    Article  CAS  Google Scholar 

  47. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–6.

    Article  CAS  PubMed  Google Scholar 

  48. De Jong D, Vasmel WL, De Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008;300(17):2030–5.

    Article  PubMed  Google Scholar 

  49. Jewell M, Spear SL, Largent J, Oefelein MG, Adams WP. Anaplastic large T-cell lymphoma and breast implants: a review of the literature. Plast Reconstr Surg. 2011;128(3):651–61.

    Article  CAS  PubMed  Google Scholar 

  50. Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31(2):240–6.

    Article  CAS  PubMed  Google Scholar 

  51. Panwalkar AW, Armitage JO. T-cell/NK-cell lymphomas: a review. Cancer Lett. 2007;253(1):1–13.

    Article  CAS  PubMed  Google Scholar 

  52. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Banerjee D. Recent advances in the pathobiology of Hodgkin’s lymphoma: potential impact on diagnostic, predictive, and therapeutic strategies. Adv Hematol. 2011;2011:439456.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Diefenbach CS, Connors JM, Friedberg JW, et al. Hodgkin lymphoma: current status and clinical trial recommendations. J Natl Cancer Inst. 2017;109(4).

    Article  CAS  Google Scholar 

  55. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Pathol. 2002;55(3):162–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Eberle FC, Mani H, Jaffe ES. Histopathology of Hodgkin’s lymphoma. Cancer J. 2009;15(2):129–37.

    Article  PubMed  Google Scholar 

  57. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812–26.

    Article  CAS  PubMed  Google Scholar 

  58. Steidl C, Diepstra A, Lee T, et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012;120(17):3530–40.

    Article  CAS  PubMed  Google Scholar 

  59. Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Smith LB. Nodular lymphocyte predominant Hodgkin lymphoma: diagnostic pearls and pitfalls. Arch Pathol Lab Med. 2010;134(10):1434–9.

    Article  PubMed  Google Scholar 

  61. Kuppers R. New insights in the biology of Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2012;2012:328–34.

    Article  Google Scholar 

  62. Swerdlow SH. Pathology. In: Dharnidharka VR, Green M, Webber SA, editors. Post-transplant lymphoproliferative disorders. Berlin: Springer-Verlag; 2010. p. 89–104.

    Chapter  Google Scholar 

  63. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2007;131(8):1209–18.

    Article  PubMed  Google Scholar 

  64. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol. 1995;103(6):748–55.

    Article  CAS  PubMed  Google Scholar 

  65. Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer. 1998;82(10):1978–87.

    Article  CAS  PubMed  Google Scholar 

  66. Krishnamurthy S, Hassan A, Frater JL, Paessler ME, Kreisel FH. Pathologic and clinical features of Hodgkin lymphoma – like posttransplant lymphoproliferative disease. Int J Surg Pathol. 2010;18(4):278–85.

    Article  PubMed  Google Scholar 

  67. Vakiani E, Nandula SV, Subramaniyam S, et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol. 2007;38(2):315–25.

    Article  PubMed  Google Scholar 

  68. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Byragani D, Baradhi K, Schendrick I, Koya S. Langerhan cell histiocytosis: a rare disorder with a rare presentation. World J Oncol. 2015;6(2):335–7.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Lee JS, Ko GH, Kim HC, Jang IS, Jeon KN, Lee JH. Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report. J Korean Med Sci. 2006;21(3):577–80.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Zhang Y, Qu Z, Fang F. Langerhans cell sarcoma originating from left knee subcutaneous tissue: a case report and literature review. Oncol Lett. 2016;12(5):3687–94.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Muslimani A, Chisti MM, Blenc AM, Boxwala I, Micale MA, Jaiyesimi I. Langerhans/dendritic cell sarcoma arising from hairy cell leukemia: a rare phenomenon. Ann Hematol. 2012;91(9):1485–7.

    Article  PubMed  Google Scholar 

  73. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Favera RD, Delsol G, De Wolf-Peeters C, Falini B, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the international lymphoma study group based on 61 cases. Histopathology. 2002;41:1–29.

    Article  CAS  PubMed  Google Scholar 

  74. Shimono J, Miyoshi H, Arakawa F, et al. Prognostic factors for histiocytic and dendritic cell neoplasms. Oncotarget. 2017;8(58):98723–32.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004;28(9):1133–44.

    Article  PubMed  Google Scholar 

  76. Pillay K, Solomon R, Daubenton JD, Sinclair-smith CC. Interdigitating dendritic cell sarcoma: a report of four paediatric cases and review of the literature. Histopathology. 2004;44(3):283–91.

    Article  CAS  PubMed  Google Scholar 

  77. Facchetti F, Pileri SA, Lorenzi L, et al. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Arch. 2017;471(4):467–89.

    Article  PubMed  Google Scholar 

  78. Horna P, Shao H, Idrees A, Glass LF, Torres-cabala CA. Indeterminate dendritic cell neoplasm of the skin: a 2-case report and review of the literature. J Cutan Pathol. 2017;44(11):958–63.

    Article  PubMed  Google Scholar 

  79. Martin Flores-Stadler E, Gonzalez-Crussi F, Greene M, Thangavelu M, Kletzel M, Chou PM. Indeterminate-cell histiocytosis: immunophenotypic and cytogenetic findings in an infant. Med Pediatr Oncol. 1999;32(4):250–4.

    Article  CAS  PubMed  Google Scholar 

  80. Chen M, Agrawal R, Nasseri-nik N, Sloman A, Weiss LM. Indeterminate cell tumor of the spleen. Hum Pathol. 2012;43(2):307–11.

    Article  PubMed  Google Scholar 

  81. Saygin C, Uzunaslan D, Ozguroglu M, Senocak M, Tuzuner N. Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol. 2013;88(2):253–71.

    Article  PubMed  Google Scholar 

  82. Chan JK, Fletcher CD, Nayler SJ, Cooper K. Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer. 1997;79(2):294–313.

    Article  CAS  PubMed  Google Scholar 

  83. Li H, Shen P, Liang Y, Zhang F. Fibroblastic reticular cell tumor of the breast: a case report and review of the literature. Exp Ther Med. 2016;11(2):561–4.

    Article  CAS  PubMed  Google Scholar 

  84. Martel M, Sarli D, Colecchia M, et al. Fibroblastic reticular cell tumor of the spleen: report of a case and review of the entity. Hum Pathol. 2003;34(9):954–7.

    Article  PubMed  Google Scholar 

  85. Dalia S, Shao H, Sagatys E, Cualing H, Sokol L. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control. 2014;21(4):290–300.

    Article  PubMed  Google Scholar 

  86. Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–82.

    Article  CAS  PubMed  Google Scholar 

  87. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester Dis. 2012;24(1):53–9.

    Google Scholar 

  88. Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2013;8(1):137.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA

    Colin McHugh, Kerry Schaffer & Carla Casulo

Authors
  1. Colin McHugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerry Schaffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carla Casulo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carla Casulo .

Editor information

Editors and Affiliations

  1. Department of Medicine, Case Western Reserve University, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Department of Medicine, University Hospital Cleveland Medical Center, Cleveland, OH, USA

    Alvin H. Schmaier

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

McHugh, C., Schaffer, K., Casulo, C. (2019). Classification of Lymphomas. In: Lazarus, H., Schmaier, A. (eds) Concise Guide to Hematology. Springer, Cham. https://doi.org/10.1007/978-3-319-97873-4_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-97873-4_29

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-97872-7

  • Online ISBN: 978-3-319-97873-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation